Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorization of MabThera (rituximab) for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphoc…
-
EMA approval · 2026-08-06EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) by Roche Registration GmbH for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis…
-
EMA approval · 2026-07-10EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA confirms authorisation of Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias; product is authorised fo…
-
EMA approval · 2026-07-08EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias, broadening its approved therapeutic use…
-
EMA approval · 2026-07-06EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB
AstraZeneca's Calquence (acalabrutinib, acalabrutinib maleate) has been authorised by EMA for chronic lymphocytic leukemia and related B-cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-17EMA Authorised: Gazyvaro (obinutuzumab) — Roche Registration GmbH
EMA authorised Gazyvaro (obinutuzumab) by Roche Registration GmbH for chronic lymphocytic leukemia (a B-cell leukemia).
-
FDA approval · 2026-02-19FDA Approved: CALQUENCE — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approves a supplemental application for CALQUENCE (acalabrutinib) submitted by AstraZeneca Pharmaceuticals LP.
-
EMA approval · 2026-02-17EMA Authorised: Imbruvica (Ibrutinib) — Janssen-Cilag International NV
EMA authorised Imbruvica (ibrutinib) for mantle cell lymphoma and chronic lymphocytic leukemia, with Janssen-Cilag International NV as the m…
-
EMA approval · 2025-10-24EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Venclyxto (venetoclax) for chronic lymphocytic leukemia (B-cell lineage) with AbbVie Deutschland as…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
FDA approval · 2025-10-17FDA Approved: GAZYVA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for GAZYVA (obinutuzumab) from Genentech to expand its approved indications.
-
EMA approval · 2025-10-06EMA Authorised: Rixathon (rituximab) — Sandoz GmbH
EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…
-
EMA approval · 2025-09-29EMA Authorised: Blitzima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorized Blitzima (rituximab) from Celltrion Healthcare Hungary Kft. for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
EMA approval · 2025-09-29EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodg…
-
EMA approval · 2025-09-19EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB
EMA authorised Calquence (acalabrutinib) for use in chronic lymphocytic leukemia and small lymphocytic lymphoma; the product is manufactured…
-
EMA approval · 2025-07-14EMA Authorised: Ruxience (rituximab) — Pfizer Europe MA EEIG
The EMA authorised Ruxience, a rituximab biosimilar by Pfizer Europe MA EEIG, for several indications including chronic lymphocytic leukemia…
-
EMA approval · 2025-07-09EMA Authorised: Ituxredi (rituximab) — Reddy Holding GmbH
The EMA authorised Ituxredi (rituximab) by Reddy Holding GmbH. It is indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and r…
-
FDA approval · 2025-06-10FDA Approved: BRUKINSA — Original Application (BeOne Medicines USA, Inc.)
The FDA approved the original application for Brukinsa (zanubrutinib) from BeOne Medicines USA, Inc., marking the U.S. approval of this BTK …
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
EMA approval · 2025-04-03EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) for multiple indications including Non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphocytic l…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
CLINICAL_TRIALS approval · 2024-12-18Clinical Trial Update: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
The document notes that pirtobrutinib is approved for marketing in relation to an expanded access program for multiple B-cell cancers, cover…
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.